Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets April 12, 2023
Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications April 12, 2023
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates April 6, 2023
First Patient Dosed in Ph 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors April 6, 2023
Positive Topline Data from BDC-1001 Ph 1 Dose-Escalation Trial in HER2-Expressing Tumors announced, Supporting Advancement to Ph 2 Clinical Studies April 6, 2023
FDA Converts to Full Approval Indication for KEYTRUDA® for Certain Adult and Pediatric Patients With Advanced MSI-H or dMMR Solid Tumors April 6, 2023
Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights March 31, 2023
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications March 31, 2023
First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine March 31, 2023
Dose Escalation Portion of Phase 1 Solid Tumors Trial of TRE-515 Produces Favorable Results in Heavily Pretreated Solid Tumor Patients March 31, 2023
Volastra Therapeutics in-licenses Clinical Stage KIF18A Inhibitor And Secures $60 Million in Series A Funding To Further Advance Cancer-Focused Pipeline March 15, 2023
Tachyon Receives Funding from CIRM for a Ph 1 Study of TACH101 in Patients with Advanced Solid Tumors March 15, 2023
Enhertu Showed Clinically Meaningful and Durable Responses Across Multiple HER2-Expressing Tumour Types in DESTINY-PanTumor02 Ph 2 Trial March 15, 2023
Kinnate Biopharma Acquires Ownership Stake from Kinnjiu Biopharma; Initiates Ph 1 Trial for Exarafenib (KIN-2787) in China February 28, 2023
Cullinan Oncology enters into an exclusive license with Harbour BioMed for the development and commercial rights of HBM7008 (CLN-418) in the U.S. February 22, 2023
Gaia Biomedicine & TreeFrog Therapeutics announce collaboration for the expansion of allogeneic NK-like cells against solid tumors February 22, 2023
Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination February 22, 2023
MD Anderson and KKR-backed Replay form new product company Syena to pioneer first-in-class TCR NK cell therapy February 22, 2023
Nectin Therapeutics and Merck to test Anti-PVR Antibody NTX1088 + KEYTRUDA® in Patients with Locally Advanced and Metastatic Solid Tumors February 22, 2023
